Myelofibrosis with myeloid metaplasia is classified broadly as a chronic myeloid disorder
and, more specifically, as a chronic myeloproliferative disease1 (Figure 1). The primary …

Therapeutic decision-making in primary myelofibrosis (PMF) is becoming more challenging
because of the increasing use of allogeneic stem cell transplantation and new …

Among the 'classic'BCR/ABL-negative chronic myeloproliferative disorders, primary
myelofibrosis (PMF) is associated with a substantial life-expectancy reduction. In this …

Age older than 65 years, hemoglobin level lower than 100 g/L (10 g/dL), white blood cell
count greater than 25× 109/L, peripheral blood blasts 1% or higher, and constitutional …

We studied the survival of 195 patients with agnogenic myeloid metaplasia (AMM)
diagnosed between 1962 and 1992 in an attempt to stratify patients into risk groups. Median …

Among 2333 consecutive patients with myelofibrosis with myeloid metaplasia (MMM) seen
at our institution, 91 fulfilled the World Health Organization (WHO) criteria for leukemic …

We assessed frequency and predictive factors for major cardiovascular (CV) events in 707
patients with primary myelofibrosis (PMF) followed in 4 European institutions. A total of 236 …

Abstract In a 20-year period, 223 patients (median age, 64.8 years) with myelofibrosis with
myeloid metaplasia (MMM) had therapeutic splenectomy at our institution. Primary …

Agnogenic myeloid metaplasia (AMM) is a chronic myeloproliferative disorder in which
patients with poor prognostic features, receiving conventional treatments, have a median …

Few investigators have evaluated the usefulness of the JAK2 V617F mutation for explaining
the phenotypic variations and for predicting the risk of major clinical events in primary …